The WHO Pharmaceuticals Newsletter provides you with the latest information
on the safety of medicines and legal actions taken by regulatory authorities
across the world.Drug safety problems not identified in clinical trials, known as signals are
published in the Uppsala Monitoring Centre's SIGNAL document and shared with
drug regulatory authorities. The WHO Advisory Committee on the Safety of
Medicinal Products (ACSoMP) recommended that SIGNAL articles should be made
public and shared with a wider audience. We have therefore started a new section
in the newsletter, to bring you these articles. We must however caution that a
"signal" is to be seen as a hypothesis together with data and arguments; it is
not only uncertain but also preliminary in nature.
The feature article in this issue gives you the conclusions from the working
groups at the thirty-fourth annual meeting of representatives of the national
centres participating in the WHO Programme for International Drug Monitoring.